focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointments of U.S. finance adviser and auditor

25 Jan 2016 07:00

RNS Number : 8221M
Motif Bio PLC
25 January 2016
 

25 January 2016

 

Motif Bio plc

("Motif" or the "Company")

 

Appointments of U.S. corporate finance adviser and auditor

 

Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces today the appointment of U.S. healthcare investment bank MTS Health Partners (MTS) to advise on its future financing options within the U.S. market. A NASDAQ listing continues to be an option for Motif in order to be aligned with several peer companies.

The Company has appointed as its auditor PricewaterhouseCoopers LLP (PwC), one of the top four multinational professional services firms in the world.

Considerable progress has also been made with plans to identify strategic partners who are interested in licensing our Phase III asset, iclaprim, outside the U.S.

Graham Lumsden, CEO of Motif, said: "For Motif to continue to grow and become a leading antibiotic company, and in order to continue to build value for our existing shareholders, it is important that we explore the capital markets in the U.S., including the potential for a NASDAQ listing. With the appointment of MTS, we can make the right decisions on how to proceed during 2016.

"The accomplishments in 2015 - listing on AIM in April, raising £25 million including the follow-on in July, being granted QIDP designation for iclaprim by the FDA, and completing the manufacture of clinical trial supplies, have strengthened the Company and positioned us for continued success in 2016."

 

 

 

Enquiries:

 

Motif Bio plc

Graham Lumsden (Chief Executive Officer)

www.motifbio.com

 

info@motifbio.com

 

Zeus Capital Limited (NOMINATED ADVISER and BROKER)

Phil Walker/Dan Bate

Dominic Wilson

 

+44 (0) 20 3829 5000

Northland Capital Partners Limited (BROKER)

Patrick Claridge/ David Hignell

John Howes (Broking)

+44 (0) 20 7382 1100

 

MC Services AG (TRADE PR)

Raimund Gabriel

Shaun Brown

 

 

 

+49 (0) 89 210 2280

+44 (0) 207 148 5998

Plumtree Capital Limited (FINANCIAL ADVISOR)

Stephen Austin

 

+44 (0) 207 183 2493

Yellow Jersey PR Limited (FINANCIAL PR)

Charles Goodwin

Dominic Barretto

 

+44 (0) 7747 788 221

Notes to Editors:

 

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif please visit www.motifbio.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUSUKRNOAAUAR
Date   Source Headline
17th Apr 20187:00 amRNSPosting of UK Annual Report and Notice of AGM
11th Apr 20182:30 pmRNSIclaprim Abstracts for ECCMID 2018 Now Online
10th Apr 20187:00 amRNSFiscal Year 2017 Results
3rd Apr 20183:29 pmRNSHolding(s) in Company
3rd Apr 20187:00 amRNSInitiation of NDA Rolling Submission for Iclaprim
20th Mar 20187:00 amRNSMotif Bio Update on NDA Submission for Iclaprim
19th Mar 20187:00 amRNSMotif Bio to present at upcoming conferences
13th Mar 20183:55 pmRNSChange of Registered Office
7th Mar 201812:29 pmRNSExercise of Warrants
1st Mar 20187:00 amRNSGrant of share options to senior management
21st Feb 20187:00 amRNSMotif Bio to Present Iclaprim Data at ECCMID 2018
19th Feb 201812:53 pmRNSExercise of Warrants
2nd Feb 20183:00 pmRNSAppointment of Interim Chief Financial Officer
29th Jan 201812:07 pmRNSSecond Price Monitoring Extn
29th Jan 201812:02 pmRNSPrice Monitoring Extension
19th Jan 20187:00 amRNSFiling of U.S. Shelf Registration
16th Jan 20187:00 amRNSMotif Bio Receives Award from CF Foundation
12th Jan 20183:12 pmRNSHolding(s) in Company
11th Jan 20183:07 pmRNSHolding(s) in Company
8th Jan 20183:23 pmRNSExercise of Warrants
5th Jan 20187:00 amRNSMotif Bio to participate in panel discussion
22nd Dec 20177:01 amRNSNotes statement from Amphion Innovations
21st Dec 20171:00 pmRNSREVIVE-1 additional results published
14th Dec 20177:00 amRNSFiling of SEC Form F-3
28th Nov 20176:24 pmRNSHolding(s) in Company
17th Nov 20177:00 amRNSHolding(s) in Company
17th Nov 20177:00 amRNSExercise of Warrants
15th Nov 20177:00 amRNSSecures up to US$20 million debt financing
9th Nov 20172:40 pmRNSExercise of Warrants
6th Nov 201712:29 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSHolding(s) in Company
6th Oct 20171:20 pmRNSHolding(s) in Company
6th Oct 20177:00 amRNSNew Pre-Clinical Data for Iclaprim at IDWeek 2017
5th Oct 20179:57 amRNSHolding(s) in Company
4th Oct 20177:00 amRNSPositive Topline Results in Phase Three Study
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
15th Sep 20172:07 pmRNSiclaprim granted Orphan Drug Designation by US FDA
8th Sep 20171:00 pmRNSHost Investor and Analyst Event on September 20
31st Aug 20171:00 pmRNSCompany to present at conferences in September
30th Aug 20177:00 amRNSHolding(s) in Company
9th Aug 20177:00 amRNSREVIVE 2 Trial Last Patient Treated
18th Jul 20177:00 amRNSAmendment to Amphion Consultancy Agreement
6th Jul 20177:00 amRNSPRESENTING THREE POSTERS ON ICLAPRIM AT ID WEEK
28th Jun 201712:41 pmRNSExercise of warrants
27th Jun 20177:00 amRNSHolding(s) in Company
22nd Jun 20173:20 pmRNSResult of General Meeting
22nd Jun 20177:00 amRNSPresents at ID Week 2017
15th Jun 20175:42 pmRNSResults of Annual General Meeting
14th Jun 20177:00 amRNSPresentation at BIO International Convention

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.